Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

21.36
+0.58002.79%
Post-market: 21.360.00000.00%18:52 EST
Volume:685.12K
Turnover:14.47M
Market Cap:2.60B
PE:-6.31
High:21.40
Open:20.96
Low:20.15
Close:20.78
52wk High:26.40
52wk Low:6.50
Shares:121.67M
Float Shares:75.23M
Volume Ratio:0.97
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3871
EPS(LYR):-3.1410
ROE:-68.13%
ROA:-21.06%
PB:5.96
PE(LYR):-6.80

Loading ...

Arcus Biosciences Inc. to Host Conference Call on Financial Results and Pipeline Update

Reuters
·
8 hours ago

Arcus Biosciences Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Jan 27

Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS

Simply Wall St.
·
Jan 17

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
Jan 13

Arcus Biosciences Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

BRIEF-Arcus Outlines Plans For Casdatifan And Its Inflammation Programs

Reuters
·
Jan 08

Arcus Biosciences Inc - Plans Three Data Readouts for Casdatifan in 2026

THOMSON REUTERS
·
Jan 08

Arcus Biosciences Inc - Expects to Fund Operations Until Second Half of 2028

THOMSON REUTERS
·
Jan 08

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Jan 08

Arcus Biosciences CFO Robert C. Goeltz II Reports Disposal of Common Shares

Reuters
·
Jan 03

Have Insiders Sold Arcus Biosciences Shares Recently?

Simply Wall St.
·
Dec 20, 2025

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Arcus Biosciences Inc - First Amendment Extends Maturity Date to Sept 1, 2030, With No Further Extension Right- SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Inc - Amendment Changes Terms for $150 Mln Loan Commitments - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Amends Loan Agreement to Access Up to $150 Million in New Financing

Reuters
·
Dec 19, 2025

Arcus Biosciences CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 19, 2025

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Benzinga_recent_news
·
Dec 13, 2025

Arcus Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-EastGroup, Boeing, Exxon Mobil

Reuters
·
Dec 13, 2025

Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating

MT Newswires Live
·
Dec 13, 2025